FEB 09, 2017 9:00 AM PST

Improved decision making in the drug discovery process using an innovative approach to modelling chronic liver disease

Speakers
  • Director & Head of Future Therapeutics & Technologies, Abbvie
    Biography
      Steve is an experienced professional in the early stages of drug discovery and development -from target identification, through project initiation up to proof of concept. This has been gained at Pfizer, AstraZeneca and Abbott/AbbVie. Steve has broad-based scientific expertise, primarily in the neuroscience area and more recently in chronic liver disease and more generally in immunology and oncology. Throughout his career Steve has managed both large and small groups of scientists and established a number of successful external collaborations with both academics and small companies. Currently Steve has two major roles - Firstly, leading the Discovery effort focused on liver disease at AbbVie, aimed at identifying treatments for NASH/NAFLD and also autoimmune diseases of the liver. Secondly, Steve head Future Therapeutics & Technologies - a team tasked with the identification and 'internalisation' of atypical therapeutic modalities.

    Abstract:

    DATE: February 9, 2017
    TIME: 9:00am PT, 12:00pm ET

    Traditional models of liver fibrosis in rodents involve many weeks of induction, with frequent injections of a pro-fibrotic agent. The most commonly used end-point in these studies is immuno-histochemical analysis of markers of fibrosis in the liver. This whole process is time-consuming, very labor-intensive in terms of animal handling, processing of the tissues and produces only a semi-quantitative measure of fibrosis. In addition, if pharmacological agents are to be explored, this means more ‘hands-on’ work for the experimentalist due to the likelihood of the need for daily dosing and adds substantially to the cost of the study because of the amounts of compound required. We have modelled the inflammatory component which drives liver fibrosis, by using the concanavalin A (conA) challenge to evoke an acute liver inflammation and the Vium ‘Digital Vivarium’ as a way of monitoring mouse behavior in response to the challenge. Acute liver inflammation evokes measurable changes in mouse behavior over the course of 24hrs and we believe these behavioral measures will be useful in testing the efficacy of pharmacological agents which suppress the inflammation.  By focusing on the inflammatory drivers of the pathology we dramatically reduce the duration of the studies, obtain a quantitative measure of the effect of the conA whilst minimizing handler intervention and reduce compound demand. Moreover, we believe the value of efficient in vivo testing of hypotheses enables us to embrace ‘systems biology’ in a way that is entirely compatible with aspects of the ‘3Rs’. Using a behavioral assessment of inflammation enables us to make rapid decisions on mechanisms and targets of interest. This reduces costs and time but maybe more importantly, promotes improved iterative decision-making regarding targets and compounds.


    Show Resources
    You May Also Like
    SEP 05, 2019 4:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 4:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    FEB 26, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    NOV 18, 2019 7:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 7:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    AUG 27, 2019 9:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 9:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    Loading Comments...
    Show Resources